The company, which is eyeing growth in Italy and Spain too, going ahead, looks to launch various new products in the US market. “Lower generic penetration in Italy, Spain, Portugal and France offers future growth potential as share of generics improves,” the company said in an investor presentation. The Hyderabad-based firm is working on plans to launch cancer treatment and injectable products in the EU. In emerging markets, the company aims to build its branded generic presence and is working on ways to deepen penetration in select markets through local manufacturing. Expanding presence in various therapeutic areas like oncology and specialty injectables is also part of the to-do list.

Source: Mint July 02, 2017 12:00 UTC